DecisionHealth, DecisionHealth - 2006 Issue 6 (June)
Injectable Lupron not in CAP
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare drug-billing issue affecting urology practices that treat prostate cancer. It discusses competitive acquisition program participation for several LH-RH therapies, notes which products are mentioned as included or excluded, and highlights why the pricing context matters for practices that buy and bill these drugs.
Why This Topic Matters
Practices that bill for injectable or implantable prostate-cancer therapies need to know how the competitive acquisition program affects reimbursement and purchasing options. The article helps readers identify the relevant drug codes and understand the general coverage context without relying on the premium discussion.
Article Sections
-
Injectable Lupron not in CAP
Introduces the reimbursement and procurement topic for prostate-cancer drug therapy in urology. It frames the discussion around competitive acquisition program participation and related pricing context.
-
Drugs on the list
Summarizes the LH-RH drugs identified as currently on the CAP drug list. The section serves as a reference point for the products discussed in the article.
What You Will Learn
- How the article frames the CAP-related billing issue for prostate-cancer drug therapy
- Which general drug categories are discussed in relation to urology practice billing
- What types of program and pricing considerations are highlighted for these therapies
- How the article distinguishes between listed and non-listed products at a high level
Who Should Read This
- Urologists
- Medical coders
- Billing staff
- Practice administrators
- Revenue cycle professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com